A retrospective, multicenter, observational study assessing the safety and effectiveness of Fingolimod in patients with relapsing-remitting multiple sclerosis (RRMS) in Taiwan
Latest Information Update: 10 Mar 2021
Price :
$35 *
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Expanded access
- 10 Mar 2021 New trial record